Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Natural antidotes and management of metal toxicity.

Amadi CN, Offor SJ, Frazzoli C, Orisakwe OE.

Environ Sci Pollut Res Int. 2019 Jun;26(18):18032-18052. doi: 10.1007/s11356-019-05104-2. Epub 2019 May 11. Review.

PMID:
31079302
2.

EDTA Chelation Therapy for the Treatment of Neurotoxicity.

Fulgenzi A, Ferrero ME.

Int J Mol Sci. 2019 Feb 26;20(5). pii: E1019. doi: 10.3390/ijms20051019. Review.

3.

Cardiac complications and iron overload in beta thalassemia major patients-a systematic review and meta-analysis.

Koohi F, Kazemi T, Miri-Moghaddam E.

Ann Hematol. 2019 Jun;98(6):1323-1331. doi: 10.1007/s00277-019-03618-w. Epub 2019 Feb 7.

PMID:
30729283
4.

Imaging features of thalassaemia.

Gosein M, Maharaj P, Balkaransingh P, Banfield R, Greene C, Latchman S, Sinanan A.

Br J Radiol. 2019 Mar;92(1095):20180658. doi: 10.1259/bjr.20180658. Epub 2018 Nov 14. Review.

PMID:
30412423
5.

Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.

Sadaf A, Hasan B, Das JK, Colan S, Alvi N.

Cochrane Database Syst Rev. 2018 Jul 12;7:CD011626. doi: 10.1002/14651858.CD011626.pub2. Review.

6.
7.

Chelation therapy to prevent diabetes-associated cardiovascular events.

Diaz D, Fonseca V, Aude YW, Lamas GA.

Curr Opin Endocrinol Diabetes Obes. 2018 Aug;25(4):258-266. doi: 10.1097/MED.0000000000000419. Review.

8.

Diagnosis and treatment of cardiac iron overload in transfusion-dependent thalassemia patients.

Siri-Angkul N, Chattipakorn SC, Chattipakorn N.

Expert Rev Hematol. 2018 Jun;11(6):471-479. doi: 10.1080/17474086.2018.1476134. Epub 2018 May 18. Review.

PMID:
29754517
9.

Chelation Therapy as a Cardiovascular Therapeutic Strategy: the Rationale and the Data in Review.

Mathew RO, Schulman-Marcus J, Nichols EL, Newman JD, Bangalore S, Farkouh M, Sidhu MS.

Cardiovasc Drugs Ther. 2017 Dec;31(5-6):619-625. doi: 10.1007/s10557-017-6759-5. Review.

PMID:
29129003
10.

Chelation therapy in cardiovascular disease: an update.

Sultan S, Murarka S, Jahangir A, Mookadam F, Tajik AJ, Jahangir A.

Expert Rev Clin Pharmacol. 2017 Aug;10(8):843-854. doi: 10.1080/17512433.2017.1339601. Epub 2017 Jun 19. Review.

PMID:
28597699
11.

Deferiprone for the treatment of transfusional iron overload in thalassemia.

Belmont A, Kwiatkowski JL.

Expert Rev Hematol. 2017 Jun;10(6):493-503. doi: 10.1080/17474086.2017.1318052. Review.

PMID:
28448199
12.
13.

Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy.

Aneni EC, Escolar E, Lamas GA.

Curr Atheroscler Rep. 2016 Dec;18(12):81. Review.

PMID:
27822681
14.

Gadolinium deposition in the brain: Lessons learned from other metals known to cross the blood-brain barrier.

Prybylski JP, Maxwell E, Coste Sanchez C, Jay M.

Magn Reson Imaging. 2016 Dec;34(10):1366-1372. doi: 10.1016/j.mri.2016.08.018. Epub 2016 Aug 28. Review.

PMID:
27580521
15.

Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy.

Lamas GA, Navas-Acien A, Mark DB, Lee KL.

J Am Coll Cardiol. 2016 May 24;67(20):2411-2418. doi: 10.1016/j.jacc.2016.02.066. Review.

16.

Oxidative Stress and Cardiovascular Dysfunction Associated with Cadmium Exposure: Beneficial Effects of Curcumin and Tetrahydrocurcumin.

Kukongviriyapan U, Apaijit K, Kukongviriyapan V.

Tohoku J Exp Med. 2016 May;239(1):25-38. doi: 10.1620/tjem.239.25. Review.

17.

Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider?

Lamas GA, Ergui I.

Expert Rev Cardiovasc Ther. 2016 Aug;14(8):927-38. doi: 10.1080/14779072.2016.1180977. Epub 2016 May 5. Review.

18.

Cardiac complications in thalassemia major.

Auger D, Pennell DJ.

Ann N Y Acad Sci. 2016 Mar;1368(1):56-64. doi: 10.1111/nyas.13026. Epub 2016 Mar 9. Review.

PMID:
26963698
19.

Chelation therapy in the treatment of cardiovascular diseases.

Ibad A, Khalid R, Thompson PD.

J Clin Lipidol. 2016 Jan-Feb;10(1):58-62. doi: 10.1016/j.jacl.2015.09.005. Epub 2015 Sep 25. Review.

PMID:
26892121
20.

Edetate Disodium-Based Treatment for Secondary Prevention in Post-Myocardial Infarction Patients.

Lamas GA, Issa OM.

Curr Cardiol Rep. 2016 Feb;18(2):20. doi: 10.1007/s11886-015-0690-9. Review.

PMID:
26797807

Supplemental Content

Loading ...
Support Center